Nebraska P&T lifts fail-first policies
Medicare & Reimbursement Advisor Weekly, October 30, 2009
Nebraska Medicaid’s P&T reclassified galantamine to preferred among cholinesterease inhibitors, according to its meeting decision September 24. (See table below.) In addition, the committee renamed the antiemetic class so that it could be more specific to the type of antiemetic, such as cannabinoids and NMDA receptor antagonists. The committee also agreed to develop new clinical criteria for non-preferred NMDA receptor antagonist Emend® (aprepitant). Patients will not be required to fail another drug first, the committee ruled. Among bone resorption suppression and related agents, the committee decided that ForteoTM prescriptions did not need to require a fail-first of nasal calcitonin; clinical criteria for Forteo will be developed to reflect this.
Most Popular
- Articles
-
- Note from Hugh
- Jury sides with blood lab technician in New Jersey whistleblower case
- Questions surround when time starts for proposed inpatient presumption
- Q/A: Should we use modifier -Q0 to override edits for ICDs?
- Five tips for an effective hospital patient safety program
- Overnight physicians in ICU show little effect on outcomes
- QAPI is coming: Is your facility preparing for its arrival?
- CMS releases updated MDS 3.0 RAI User's Manual
- Tip: Review codes that are now packaged
- Maine comes in first in hospital safety
- E-mailed
-
- Questions surround when time starts for proposed inpatient presumption
- Jury sides with blood lab technician in New Jersey whistleblower case
- Q/A: Should we use modifier -Q0 to override edits for ICDs?
- Overnight physicians in ICU show little effect on outcomes
- Tip: Review codes that are now packaged
- QAPI is coming: Is your facility preparing for its arrival?
- ACDIS/AHIMA brief provides guidance on query best practices
- Maine comes in first in hospital safety
- Surgical residents disapprove of duty hour restrictions
- Tip: Nursing documentation requirements for observation services
- Searched